Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04054921 · ClinicalTrials.gov registry record · Phase 2
Safety Study for Beta Thalassemia Subjects on PTG-300
A Phase 2 study, sponsored by Protagonist Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT04054921 is a Phase 2 study that has completed, run by Protagonist Therapeutics. The registered enrollment target is 34 participants.
The verdict
NCT04054921, a Phase 2 study, has completed, sponsored by Protagonist Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.
Interventions
- DRUG PTG-300
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-05-10 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04054921
The ClinicalTrials.gov registry entry for NCT04054921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protagonist Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PTG-300 is the first listed.
NCT04054921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04054921 about?
NCT04054921 is a clinical study titled "Safety Study for Beta Thalassemia Subjects on PTG-300". In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.
What is the current status of trial NCT04054921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2019-05-10. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT04054921?
The interventions under investigation include: PTG-300 (DRUG).
Who is sponsoring clinical trial NCT04054921?
This trial is sponsored by Protagonist Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.